TALEN

TALEN1-cnr1

ID

ZDB-TALEN-160719-1

Name

TALEN1-cnr1

Previous Names

None

Target

cnr1 (1)

Target Sequence 1

5' - TCAGAACCATCACCTCCG - 3'

Target Sequence 2

5' - TAGCCGATGTCATTGGAG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
zf679	cnr1

Expression

Gene expression in Wild Types + TALEN1-cnr1

No data available

Phenotype

Phenotype resulting from TALEN1-cnr1

No data available

Phenotype of all Fish created by or utilizing TALEN1-cnr1

Phenotype	Fish	Conditions	Figures
locomotory behavior process quality, ameliorated	cnr1^zf679/zf679	chemical treatment by environment: cannabinoid receptor agonist	Fig. 5 from Luchtenburg et al., 2019
locomotory behavior increased process quality, abnormal	cnr1^zf679/zf679	chemical treatment by environment: cannabinoid receptor agonist	Fig. 5 from Luchtenburg et al., 2019
whole organism srm expression decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
liver decreased size, abnormal	cnr1^zf679/zf679 (TU)	control	Fig. 1 , Fig. 6 , Fig. 7 from Liu et al., 2016
whole organism srebf1 expression decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 7 from Liu et al., 2016
liver methionine decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
liver lipid increased amount, abnormal	cnr1^zf679/zf679 (TU)	chemical treatment: ethanol	Fig. 6 from Liu et al., 2016
liver fabp10a expression decreased distribution, abnormal	cnr1^zf679/zf679 (TU)	control	Fig. 1 , Fig. 6 , Fig. 7 from Liu et al., 2016
liver S-adenosyl-L-methionine decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
whole organism fabp10a expression decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 1 from Liu et al., 2016
hepatocyte morphology, ameliorated	cnr1^zf679/zf679 (TU)	chemical treatment: methionine	Fig. 6 from Liu et al., 2016
hepatocyte morphology, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 3 , Fig. 6 from Liu et al., 2016
liver homoserine decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
whole organism ahcy expression decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
whole organism srebf2 expression decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 7 from Liu et al., 2016
liver lipid increased amount, abnormal	cnr1^zf679/zf679 (TU)	chemical treatment: ethanol, chemical treatment: methionine	Fig. 6 from Liu et al., 2016
liver size, ameliorated	cnr1^zf679/zf679 (TU)	chemical treatment: cysteine	Fig. 6 from Liu et al., 2016
common bile duct morphology, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 3 , Fig. 4 from Liu et al., 2016
gall bladder lipase activity absent, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 3 from Liu et al., 2016
liver cysteine decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
bile accumulation liver, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 4 from Liu et al., 2016
liver lipid increased amount, abnormal	cnr1^zf679/zf679 (TU)	chemical treatment: cysteine, chemical treatment: ethanol	Fig. 6 from Liu et al., 2016
protein methylation decreased occurrence, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
liver size, ameliorated	cnr1^zf679/zf679 (TU)	chemical treatment: methionine	Fig. 6 from Liu et al., 2016
whole organism mthfr expression increased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
methionine metabolic process process quality, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
liver serine decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
common bile duct decreased branchiness, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 3 from Liu et al., 2016
liver S-adenosyl-L-homocysteine decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
common bile duct development process quality, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 3 , Fig. 4 from Liu et al., 2016
intestine lipase activity decreased occurrence, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 3 from Liu et al., 2016
liver homocysteine decreased amount, abnormal	cnr1^zf679/zf679 (TU)	standard conditions	Fig. 5 from Liu et al., 2016
liver cell population proliferation decreased rate, abnormal	cnr1^zf679/zf679; as3Tg	standard conditions	Fig. 2 from Liu et al., 2016
liver decreased size, abnormal	cnr1^zf679/zf679; as3Tg	standard conditions	Fig. 2 , Fig. 7 from Liu et al., 2016
hepatocyte decreased amount, abnormal	cnr1^zf679/zf679; as3Tg	standard conditions	Fig. 1 from Liu et al., 2016
liver decreased size, abnormal	cnr1^zf679/zf679; cnr2^zf680/zf680 (TU)	standard conditions	Fig. 1 from Liu et al., 2016
hepatocyte morphology, abnormal	cnr1^zf679/zf679; cnr2^zf680/zf680 (TU)	control	Fig. 6 from Liu et al., 2016
liver fabp10a expression decreased distribution, abnormal	cnr1^zf679/zf679; cnr2^zf680/zf680 (TU)	standard conditions	Fig. 1 from Liu et al., 2016

Citations